Innovative ways to cure vaginal infections
Bacterial vaginosis (BV) is one of the most common vaginal infections, affecting nearly one in three women ages 15-44. While women with BV often don’t notice any symptoms, it significantly increases the risk of other sexually transmitted infections like HIV. BV during pregnancy increases the risk of preterm birth. Approaches to treating BV haven't changed in several decades, and recurrence rates are high even following successful treatment.
The study, conducted at four centers nationwide including UCSF, will include more than 200 women and follow them over time. “If LACTIN-V is proven to work, clinicians will finally have an improved therapy to prevent BV for their patients,” said Bixby’s Dr. Craig Cohen, clinical lead for the trial. Dr. Anke Hemmerling is a co-investigator and adds that “LACTIN-V is the first vaginal Lactobacillus product tested in an advanced clinical study. It has the potential to prevent not only BV, but also reduce other STIs and preterm birth.”
For more information, visit the study website.